The trial met its primary end point of progression-free survival in patients with an International Prognostic Index (IPI) ...

Epcoritamab combined with R-CHOP significantly improved progression free survival in patients with newly diagnosed DLBCL across both the primary endpoint and total populations.

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging ...

A new systematic review finds that about one in five adults with diffuse large B-cell lymphoma develops febrile neutropenia ...

AbbVie ( ABBV) and Genmab ( GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell ...

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

Company AnnouncementCOPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026EPCORE DLBCL-2 is the first Phase 3 study of a bispecific ...